A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Sep 2021 Results assessing effectiveness and safety of trastuzumab in patients with HER2-positive mGC in China published in the Oncologist
03 Jul 2021 Results (n=310) of a comparative analysis from ToGA and EVIDENCE studies showing the effectiveness of trastuzumab in Asian patients with HER2+ mGC presented at the 23rd World Congress on Gastrointestinal Cancer
25 Jan 2020 Results (n=758) for Cohort III and Cohort V of treatment patterns and long-term clinical outcomes in Chinese patients with nonmetastatic gastric cancer has been presented at the 2020 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com